sure - I don't expect the current increase to be sustainable, noting what you said.
But the management is seeming very active in the last 6 months, onboarding the new VC on the advisory board might have some implications to this increase (maybe). Also a positive future expectation might be being priced in now (maybe).
Lot of if's and maybe's - so let's see how it plays out.
Ann: Strategic Partnership for Clinical R&D in China worth $4M, page-14
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
